Capital Advisors Incok buys $10,714,198 stake in Laboratory Corp. of America Holdings (LH)

Laboratory Corp. of America Holdings (LH) : Capital Advisors Incok scooped up 2,476 additional shares in Laboratory Corp. of America Holdings during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 75,998 shares of Laboratory Corp. of America Holdings which is valued at $10,714,198.Laboratory Corp. of America Holdings makes up approximately 1.59% of Capital Advisors Incok’s portfolio.

Other Hedge Funds, Including , Nine Chapters Capital Management sold out all of its stake in LH during the most recent quarter. The investment firm sold 33,200 shares of LH which is valued $4,626,420.Artemis Investment Management Llp boosted its stake in LH in the latest quarter, The investment management firm added 12,300 additional shares and now holds a total of 71,805 shares of Laboratory Corp. of America Holdings which is valued at $9,880,368. Laboratory Corp. of America Holdings makes up approx 0.26% of Artemis Investment Management Llp’s portfolio.Capital City Trust Cofl reduced its stake in LH by selling 195 shares or 0.95% in the most recent quarter. The Hedge Fund company now holds 20,375 shares of LH which is valued at $2,828,458. Laboratory Corp. of America Holdings makes up approx 1.11% of Capital City Trust Cofl’s portfolio.Davenport Co boosted its stake in LH in the latest quarter, The investment management firm added 75 additional shares and now holds a total of 5,872 shares of Laboratory Corp. of America Holdings which is valued at $798,005. Laboratory Corp. of America Holdings makes up approx 0.01% of Davenport Co’s portfolio.

Laboratory Corp. of America Holdings closed down -0.65 points or -0.47% at $138.24 with 8,11,364 shares getting traded on Wednesday. Post opening the session at $139.14, the shares hit an intraday low of $137.9 and an intraday high of $139.96 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Laboratory Corp. of America Holdings reported $2.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.30. The company had revenue of $2382.00 million for the quarter, compared to analysts expectations of $2334.01 million. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.09 EPS.

Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing patient diagnosis and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment which includes core testing as well as genomic and esoteric testing; and the Other segment which consists of the Company’s non-United States clinical diagnostic laboratory operations in Ontario Canada. It also provides specialty testing services in the areas of allergy clinical trials diagnostic genetics women’s health cardiovascular disease identity forensics infectious disease endocrinology oncology coagulation occupational testing and pain management.

Leave a Reply

Laboratory Corp. of America Holdings - Is it time to Sell?

Top Brokerage Firms are advising their investors on Laboratory Corp. of America Holdings. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.